Answers are grounded in this paper and cite their sources.
Aim Anti-angiogenic therapy with bevacizumab has shown promise in hereditary hemorrhagic telangiectasia (HHT), although evidence remains limited. This retrospective cohort study evaluated bleeding severity, transfusion and iron requirements, anemia, and quality of life in patients receiving intravenous bevacizumab. Methods Eight patients with HHT receiving intravenous bevacizumab were included. Disease severity and health-related quality of life were assessed using the Epistaxis Severity Score (ESS) and SF-36 questionnaire, respectively. Results Five patients were female, and three were male, with a median follow-up of 30 months. The mean age was 65 years (range: 44-70). The mean ESS decreased from 7.75±2.7 to 1.4±1.2 after treatment. The median transfusion requirement declined from 5 units before treatment to none during the first 2 years. Median hemoglobin increased from 9.5 g/dL at baseline to 13.1, 14.55, 12.95, and 12.5 g/dL at 3, 6, 12, and 24 months, respectively. Mild headache and increased systolic blood pressure occurred in two patients each. All SF-36 scores improved after treatment. Conclusion In this small retrospective cohort, intravenous bevacizumab was associated with improved bleeding control, anemia, and quality-of-life outcomes, with no serious toxicity observed during follow-up
No takes yet. Share an insight, caveat, or question.
Avcı et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: